Cover Image

A case of de novo psoriasis induced by atezolizumab in a patient with advanced lung cancer

Saved in:

Bibliographic Details
Main Authors:	Shigeruko Iijima (Author), Kunihiko Miyazaki (Author), Shinya Sato (Author), Takahide Kodama (Author)
Format:	Book
Published:	Frontiers Media S.A., 2019-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A case of pregabalin‐induced drug eruptions accompanied by extremely high serum thymus and activation‐regulated chemokine levels
by: Shigeruko Iijima, et al.
Published: (2021)

Atezolizumab-Induced Acrodermatitis and Pustular Psoriasis in a Patient with Non-Small Cell Lung Cancer: A Rare Case Report
by: Davide Fattore, et al.
Published: (2024)

Atezolizumab-Induced Bell's Palsy in a Patient With Small Cell Lung Cancer
by: Asim Kichloo MD, et al.
Published: (2020)

Pustular psoriasis triggered by therapy with atezolizumab and bevacizumab
by: Mariani Magnus da Luz Andrade, et al.
Published: (2024)

Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer
by: Lee Cheng Phua, et al.
Published: (2020)

Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
by: Miriam Alonso-García, et al.
Published: (2022)

Atezolizumab-Induced Stevens-Johnson Syndrome in a Patient with Non-Small Cell Lung Carcinoma
by: Phatcharawat Chirasuthat, et al.
Published: (2018)

Killing a fly with a sledgehammer: Atezolizumab exposure in real‐world lung cancer patients
by: Sophie Marolleau, et al.
Published: (2023)

Effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in metastatic non-small cell lung cancer
by: Amparo Burgos-San José, et al.
Published: (2021)

Comparative analysis of using atezolizumab vs. durvalumab in combination with platinum-containing chemotherapy in adult patients with advanced small cell lung cancer
by: I. S. Krysanov, et al.
Published: (2023)

Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer
by: Matteo Franchi, et al.
Published: (2022)

Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US
by: Yingcheng Wang, et al.
Published: (2021)

Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
by: Facchinetti F, et al.
Published: (2018)

Twenty cases of allergic contact dermatitis due to benzoyl peroxide in acne patients in Japan
by: Shigeruko Iijima, et al.
Published: (2019)

Linear IgA bullous dermatosis induced by atezolizumab: a case report
by: Seba Almutairi, et al.
Published: (2024)

A case of urticarial vasculitis associated with atezolizumab
by: Jade N. Young, BS, et al.
Published: (2024)

Downstaging with atezolizumab-bevacizumab: a case series
by: Anand V. Kulkarni, et al.
Published: (2024)

Pharmacoeconomic analysis of atezolizumab plus nab-paclitaxel in the treatment of the advanced or metastatic triple-negative breast cancer
by: A S Kolbin, et al.
Published: (2020)

Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis
by: Xiaoyan Liu, et al.
Published: (2021)

A Rare Case Presentation of Vitiligo Associated With Atezolizumab
by: Kemnasom Nwanwene MD, et al.
Published: (2023)

Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
by: Tae Hyun Kim, et al.
Published: (2023)

Neutrophilic dermatosis with necrobiotic changes as an unusual manifestation after the first shot of a COVID‐19 mRNA vaccine together with a high fever and liver injury
by: Shigeruko Iijima, et al.
Published: (2023)

Atezolizumab Plus Bevacizumab-induced Recalcitrant Pyoderma Gangrenosum Treated with Baricitinib: A Case Report
by: Han Seul Kim, et al.
Published: (2023)

Case of durvalumab‐induced annular psoriasiform dermatitis in lung cancer
by: Asako Ota, et al.
Published: (2022)

Safety and efficacy of atezolizumab in the treatment of cancers: a systematic review and pooled-analysis
by: Tie Y, et al.
Published: (2019)

Hyperprogression in a Patient With Hepatocellular Cancer Treated With Atezolizumab and Bevacizumab: A Case Report and Review of Literature
by: Balraj Singh MD, et al.
Published: (2021)

Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens
by: Li LF, et al.
Published: (2024)

Atezolizumab-induced encephalitis in a patient with metastatic breast cancer: a case report and review of neurological adverse events associated with checkpoint inhibitors
by: Rita Nade, et al.
Published: (2021)

A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
by: Yukinobu Watanabe MD, PhD, et al.
Published: (2021)

Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination
by: Takahiro Niimura, et al.
Published: (2023)

Letter regarding "Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab"
by: Sun Hyun Bae, et al.
Published: (2023)

Tumor Time‐Course Predicts Overall Survival in Non‐Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow‐Up Time
by: Ida Netterberg, et al.
Published: (2020)

Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)
by: Benjamin Wu, et al.
Published: (2022)

Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2)
by: Solange Peters, et al.
Published: (2022)

A Case of Eosinophilic Pustular Folliculitis with Vegetating Lesions on the Lower Legs and Feet Resembling Pemphigus Vegetans
by: Masakazu Kakurai, et al.
Published: (2023)

Cost-effectiveness analysis of atezolizumab in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen: a United Kingdom health care perspective
by: Yunlin Jiang, et al.
Published: (2023)

Macular‐type cutaneous adverse reaction due to atezolizumab and pembrolizumab
by: Hitomi Sugino, et al.
Published: (2022)

Product review on the Anti-PD-L1 antibody atezolizumab
by: Neil J. Shah, et al.
Published: (2018)

Development and Evaluation of a Quantitative Systems Pharmacology Model for Mechanism Interpretation and Efficacy Prediction of Atezolizumab in Combination with Carboplatin and Nab-Paclitaxel in Patients with Non-Small-Cell Lung Cancer
by: Chen-Yu Wang, et al.
Published: (2024)

A case of nearly complete response in hepatocellular carcinoma with disseminated lung metastasis by combination therapy of nivolumab and ipilimumab after treatment failure of atezolizumab plus bevacizumab
by: Hyung Jun Kim, et al.
Published: (2023)